Replies to post #141528 on Biotech Values

[biomaven0]

RIGL's fostamatinib, which is a Syk inhibitor, might not share this same risk

I posted about this as a theoretical concern some years ago:

http://www.siliconinvestor.com/readmsg.aspx?msgid=26043521

Peter